Zacks Investment Research lowered shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.
According to Zacks, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. “
Other equities analysts also recently issued reports about the stock. Cowen and Company reiterated a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 1st. HC Wainwright reiterated a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Piper Jaffray Cos. reiterated a buy rating and set a $16.00 price target on shares of Nivalis Therapeutics in a report on Tuesday, August 30th. Finally, Raymond James Financial Inc. assumed coverage on shares of Nivalis Therapeutics in a report on Tuesday, September 13th. They set an outperform rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $13.75.
Nivalis Therapeutics (NASDAQ:NVLS) opened at 7.69 on Wednesday. Nivalis Therapeutics has a 52 week low of $3.68 and a 52 week high of $9.45. The company’s market cap is $119.22 million. The firm’s 50 day moving average is $7.65 and its 200-day moving average is $5.45.
Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings results on Monday, August 1st. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.03. On average, analysts predict that Nivalis Therapeutics will post ($2.29) earnings per share for the current fiscal year.
In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of the business’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total value of $46,327.20. Following the completion of the sale, the executive vice president now directly owns 18,056 shares of the company’s stock, valued at approximately $143,725.76. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.00% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new stake in Nivalis Therapeutics during the second quarter valued at about $105,000. State Street Corp boosted its stake in Nivalis Therapeutics by 4.5% in the first quarter. State Street Corp now owns 44,495 shares of the company’s stock valued at $186,000 after buying an additional 1,900 shares during the period. Opaleye Management Inc. bought a new stake in Nivalis Therapeutics during the first quarter valued at about $417,000. AXA boosted its stake in Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock valued at $2,455,000 after buying an additional 139,652 shares during the period. Finally, Sabby Management LLC boosted its stake in Nivalis Therapeutics by 31.5% in the first quarter. Sabby Management LLC now owns 662,058 shares of the company’s stock valued at $2,761,000 after buying an additional 158,463 shares during the period. 83.12% of the stock is owned by institutional investors.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.